(2.2) Refer to the Full Prescribing Information for additional important administration instructions about MOUNJARO presentations
MOUNJARO 12.5mg KwikPen is an injection in a pre-filled pen containing tirzepatide the active substance at a strength of 12.5mg per 0.6ml dose, manufactured by Eli Lilly and Company Limited.[1][5] Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated for patients with type 2 diabetes mellitus and, in markets where MOUNJARO carries the weight management indication, for eligible adults as an adjunct to diet and exercise.[4][5] The 12.5mg dose is the high-dose titration or maintenance step immediately below the maximum 15 mg of tirzepatide in the approved escalation schedule, with each KwikPen delivering four once-weekly subcutaneous doses.[1][5] Looking to buy MOUNJARO 12.5mg KwikPen online
This product entry covers the primary NDC 70069-171 and 2 associated package configurations
If you choose to drink, keep consumption minimal and infrequent
However, the most vital of these is the KX modifier
Oral B12 supplementation generally takes longer to produce noticeable effects than intramuscular injections, with patients typically experiencing improvements within 24 weeks
